Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL0137 in Relapsed or Refractory Solid Tumors, CNS Tumors, and Lymphoma
NCT04870944Phase 2Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cbl0137 in solid tumor, central nervous system tumor, lymphoma and 2 more, sponsored by Children's Oncology Group. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 21 days, Dose Limiting Toxicities at 21 days and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
cbl0137
03
Conditions
solid tumorcentral nervous system tumorlymphomadiffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04870944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870944.